Foramen magnum meningioma

Summary

Foramen magnum meningioma (MONDO:0003109) is a disease. A subtype of skull base meningioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	foramen magnum meningioma
Mondo ID	MONDO:0003109
DOID	DOID:4708
NCIT	C5280
UMLS	C1333630
MedGen	232512
GARD	0023369
Anatomy (UBERON)	UBERON:0003687
Is cancer (heuristic)	no

Also known as: foramen magnum meningioma (disease) · meningioma (disease) of foramen magnum · meningioma of Foramen magnum · meningioma of the Foramen magnum

Disease family

This is a subtype of skull base meningioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › head and neck neoplasm › skull neoplasm › skull base neoplasm › skull base meningioma › foramen magnum meningioma

Related subtypes (9): cavernous sinus meningioma, clivus meningioma, multiple skull base meningioma, diaphragma sellae meningioma, suprasellar meningioma, petroclival meningioma, sphenoorbital meningioma, sphenocavernous meningioma, pituitary stalk meningioma

Subtypes (2): anterior foramen magnum meningioma, posterior foramen magnum meningioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.